EFM
NTLA icon

E Fund Management’s Intellia Therapeutics NTLA Stock Holding History

E Fund Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$381K Sell
22,501
-2,609
-10% -$36.5K 0.01% 336
2026
Q1 		$322K Buy
+25,110
New +$320K 0.01% 376
2025
Q2 		$135K Sell
14,339
-2,492
-15% -$20.5K 0.01% 369
2025
Q1 		$120K Sell
16,831
-1,222
-7% -$12.3K 0.01% 379
2024
Q4 		$210K Buy
18,053
+1,634
+10% +$25.5K 0.01% 357
2024
Q3 		$337K Buy
16,419
+3,754
+30% +$86.6K 0.02% 239
2024
Q2 		$283K Sell
12,665
-1,795
-12% -$42.7K 0.02% 241
2024
Q1 		$398K Sell
14,460
-2,091
-13% -$58.1K 0.02% 222
2023
Q4 		$505K Buy
16,551
+4,476
+37% +$129K 0.03% 161
2023
Q3 		$382K Buy
12,075
+1,745
+17% +$67.7K 0.03% 174
2023
Q2 		$421K Sell
10,330
-452
-4% -$18.3K 0.03% 157
2023
Q1 		$402K Sell
10,782
-321
-3% -$12.6K 0.03% 165
2022
Q4 		$387K Buy
11,103
+3,710
+50% +$176K 0.03% 191
2022
Q3 		$414K Sell
7,393
-2,922
-28% -$181K 0.04% 173
2022
Q2 		$534K Buy
10,315
+5,938
+136% +$302K 0.05% 133
2022
Q1 		$318K Buy
+4,377
New +$371K 0.01% 181

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

E Fund Management's NTLA Position: Q2 2026 in Review

E Fund Management reduced its Intellia Therapeutics (NTLA) stake by 10% in Q2 2026, selling an estimated $36.5K and leaving 22,501 shares worth $381K. The position accounts for 0.01% of the portfolio, ranked #336.

E Fund Management first reported a position in NTLA in Q1 2022 and has held it in 16 quarters since. The position peaked at $534K in Q2 2022. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • E Fund Management held 22,501 shares of Intellia Therapeutics worth $381K as of Q2 2026.
  • E Fund Management sold 2,609 Intellia Therapeutics shares in Q2 2026, an estimated $36.5K.
  • Intellia Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #336 holding.
  • E Fund Management first reported a position in Intellia Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • E Fund Management's Intellia Therapeutics position peaked at $534K in Q2 2022.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.